Should we be targeting type 1 interferons in antiphospholipid syndrome?

Full text
Author(s):	Santos, Gabrielle de Mello ; Saldanha, Artur ; Orsi, Fernanda Andrade Total Authors: 3
Document type:	Journal article
Source:	Clinical Immunology; v. 255, p. 8-pg., 2023-09-09.
Abstract
Systemic autoimmune diseases are characterized by increased production of type I interferon (IFN-1) and upregulation of IFN-1-inducible genes, suggesting an important role of the IFN-1 pathway in their pathogenesis. Recent studies have demonstrated increased IFN-1 expression in both primary and secondary antiphospholipid syndrome (APS), along with increased toll-like receptor type 9 activity and plasmacytoid dendritic cell function. The increasing knowledge of the association between IFN-1 and APS pathology may provide a rationale for conducting clinical trials to assess the efficacy of IFN-1-targeting drugs in reducing APS-related complications. In this narrative review, we summarize the current knowledge on the role of IFN-1 in APS pathogenesis, explore its clinical implications, and examine the existing evidence regarding therapeutic options that have been investigated to date. (AU)

FAPESP's process:	20/12630-2 - Role of neutrophil extracellular traps (NETs) and platelet activation in immunothrombosis related to COVID-19 and inhibitory effect of substances that increase intracellular levels of cyclic nucleotides
Grantee:	Fernanda Loureiro de Andrade Orsi
Support Opportunities:	Regular Research Grants